{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=46",
    "query": {
      "intervention": "T cells",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 3574,
    "total_pages": 358,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:09:42.544Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05952804",
      "title": "IVIG for Infection Prevention After CAR-T-Cell Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Infusion (Human), 10% Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-CD19 CAR T Cells Preparation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2024-06-10",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Miami, Florida • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05952804"
    },
    {
      "nct_id": "NCT06626919",
      "title": "Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscular Diseases",
        "Neuromuscular Manifestations",
        "Autoimmune",
        "Autoimmune Diseases",
        "Autoimmune Diseases of the Nervous System",
        "Myasthenia Gravis",
        "Muscle Weakness"
      ],
      "interventions": [
        {
          "name": "anito-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-30",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06626919"
    },
    {
      "nct_id": "NCT00467532",
      "title": "Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Burns",
        "Cytomegalovirus"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-03",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2013-01-17",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467532"
    },
    {
      "nct_id": "NCT05397093",
      "title": "ITIL-306 in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ITIL-306",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Instil Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2022-08-24",
      "completion_date": "2026-03-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • New York, New York",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397093"
    },
    {
      "nct_id": "NCT00045500",
      "title": "UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "7-hydroxystaurosporine",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Frederick, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045500"
    },
    {
      "nct_id": "NCT03391232",
      "title": "PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "PolyPEPI1018 CRC Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Treos Bio Zrt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2018-05-03",
      "completion_date": "2019-07-17",
      "has_results": true,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03391232"
    },
    {
      "nct_id": "NCT00710892",
      "title": "CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Non-Hodgkin's Lymphoma",
        "Myelodysplastic Syndrome",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Allodepleted T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-12",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00710892"
    },
    {
      "nct_id": "NCT04520711",
      "title": "Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Epithelial Neoplasms"
      ],
      "interventions": [
        {
          "name": "TCR-transduced T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CDX-1140",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 24,
      "start_date": "2022-02-08",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04520711"
    },
    {
      "nct_id": "NCT01590732",
      "title": "Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mycosis Fungoides",
        "Recurrent Anaplastic Large Cell Lymphoma",
        "Recurrent Angioimmunoblastic T-Cell Lymphoma",
        "Recurrent Enteropathy-Associated T-Cell Lymphoma",
        "Recurrent Hepatosplenic T-Cell Lymphoma",
        "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Angioimmunoblastic T-Cell Lymphoma",
        "Refractory Enteropathy-Associated T-Cell Lymphoma",
        "Refractory Hepatosplenic T-Cell Lymphoma",
        "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2012-10-29",
      "completion_date": "2018-05-02",
      "has_results": false,
      "last_update_posted_date": "2018-09-19",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590732"
    },
    {
      "nct_id": "NCT01290692",
      "title": "Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Grade IV Glioma",
        "Grade IV Astrocytoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "TVI-Brain-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TVAX Biomedical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-06",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-11-15T18:09:42.544Z",
      "location_count": 4,
      "location_summary": "Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Green Bay",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290692"
    }
  ]
}